Clinical Trials

Showing trials with last updates posted in 2026.

NCT06047717 | RECRUITING | NA
40 participants

Vision Loss Impact on Navigation in Virtual Reality

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-25
Start Date:
2023-11-28
Completion:
2028-10-31
Conditions
  • Stroke, Ischemic
  • Quadrantanopia
  • Hemianopsia, Homonymous
  • Hemianopia, Homonymous
  • Hemianopia
  • Hemianopsia
  • Occipital Lobe Infarct
  • Visual Field Defect, Peripheral
  • Vision Loss Partial
  • Quadrantanopsia
  • Stroke Hemorrhagic
Interventions
  • OTHER
No Results Yet
NCT06017193 | ACTIVE_NOT_RECRUITING
140 participants

Ultrasound for Socket Healing Evaluation

Study Type:
OBSERVATIONAL
Last Updated:
2026-08-25
Start Date:
2024-07-25
Completion:
2027-07-01
Conditions
  • Healing Wound
  • Alveolar; Wound
  • Alveolar Bone Loss
  • Image
  • Dent Disease
No Results Yet
NCT05997056 | COMPLETED | PHASE2
12 participants

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-25
Start Date:
2023-10-20
Completion:
2025-10-03
Conditions
  • Neuroendocrine Tumors
  • NET
  • Pancreatic Neuroendocrine Tumor
  • Gastrointestinal Neuroendocrine Tumor
  • Pulmonary Neuroendocrine Tumor
Interventions
  • DRUG
NCT05992415 | NOT_YET_RECRUITING | NA
7085 participants

Know Your Pressures NYC

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-25
Start Date:
2027-07-01
Completion:
2032-06-30
Conditions
  • Glaucoma
  • Hypertension
  • Glaucoma, Suspect
  • Elevated Blood Pressure
Interventions
  • OTHER
No Results Yet
NCT05886049 | RECRUITING | PHASE1
38 participants

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-25
Start Date:
2024-06-20
Completion:
2027-12-31
Conditions
  • Acute Myeloid Leukemia
  • Acute Myeloid Leukemia With KMT2A Rearrangement
  • Acute Myeloid Leukemia With NPM1 Mutation
  • Secondary Acute Myeloid Leukemia
Interventions
  • PROCEDURE
  • DRUG
No Results Yet
NCT05761171 | ACTIVE_NOT_RECRUITING | PHASE2
78 participants

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-25
Start Date:
2024-01-08
Completion:
2027-12-31
Conditions
  • Recurrent Acute Leukemia of Ambiguous Lineage
  • Recurrent Acute Lymphoblastic Leukemia
  • Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage
  • Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged
  • Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia
  • Recurrent Mixed Phenotype Acute Leukemia
  • Refractory Acute Leukemia of Ambiguous Lineage
  • Refractory Acute Lymphoblastic Leukemia
  • Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage
  • Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged
  • Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia
  • Refractory Mixed Phenotype Acute Leukemia
Interventions
  • PROCEDURE
  • DRUG
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page